Literature DB >> 21733508

Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.

Paulina A Essah1, James A Arrowood, Kai I Cheang, Swati S Adawadkar, Dale W Stovall, John E Nestler.   

Abstract

In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10). After 3 months, both treatments had similar effects on androgen levels, lipid profile, insulin sensitivity, and serum inflammatory markers, but flow-mediated dilatation increased by 69.0% in the metformin plus OC group while it remained unchanged in the OC group. CLINICAL TRIAL REGISTRATION NO: NCT00682890.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21733508      PMCID： PMC4480914          DOI： 10.1016/j.fertnstert.2011.05.091

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  26 in total

1.  Endothelial function across an oral contraceptive cycle in women using levonorgestrel and ethinyl estradiol.

Authors:  Britta N Torgrimson; Jessica R Meendering; Paul F Kaplan; Christopher T Minson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-02-02       Impact factor: 4.733

2.  Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Kai I Cheang; Jean-Patrice Baillargeon; Paulina A Essah; Richard E Ostlund; Teimuraz Apridonize; Leila Islam; John E Nestler
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

3.  Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

Authors:  R J Norman; L Masters; C R Milner; J X Wang; M J Davies
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

4.  Importance of glucose per se to intravenous glucose tolerance. Comparison of the minimal-model prediction with direct measurements.

Authors:  M Ader; G Pacini; Y J Yang; R N Bergman
Journal:  Diabetes       Date:  1985-11       Impact factor: 9.461

5.  Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp.

Authors:  R N Bergman; R Prager; A Volund; J M Olefsky
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

6.  Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.

Authors:  Koray Elter; Gonca Imir; Fatih Durmusoglu
Journal:  Hum Reprod       Date:  2002-07       Impact factor: 6.918

Review 7.  Combination contraceptives: effects on weight.

Authors:  Maria F Gallo; Laureen M Lopez; David A Grimes; Kenneth F Schulz; Frans M Helmerhorst
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

8.  Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.

Authors:  Laure Morin-Papunen; Ilkka Vauhkonen; Riitta Koivunen; Aimo Ruokonen; Hannu Martikainen; Juha S Tapanainen
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

9.  Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.

Authors:  Jie Wu; Yiqing Zhu; Yunfei Jiang; Yaoping Cao
Journal:  Gynecol Endocrinol       Date:  2008-07       Impact factor: 2.260

10.  Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.

Authors:  Helena J Teede; Caroline Meyer; Samantha K Hutchison; Sophia Zoungas; Barry P McGrath; Lisa J Moran
Journal:  Fertil Steril       Date:  2008-11-18       Impact factor: 7.329
View more
  7 in total

1.  Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.

Authors:  Adeola A Adeniji; Paulina A Essah; John E Nestler; Kai I Cheang
Journal:  J Womens Health (Larchmt)       Date:  2016-02-12       Impact factor: 2.681

2.  Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial.

Authors:  Andrew P Demidowich; Jordan A Levine; Ginikanwa I Onyekaba; Shahzaib M Khan; Kong Y Chen; Sheila M Brady; Miranda M Broadney; Jack A Yanovski
Journal:  Diabetes Obes Metab       Date:  2019-04-02       Impact factor: 6.577

3.  Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.

Authors:  Eloise Fraison; Elena Kostova; Lisa J Moran; Sophia Bilal; Carolyn C Ee; Christos Venetis; Michael F Costello
Journal:  Cochrane Database Syst Rev       Date:  2020-08-13

4.  The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Elfatih A Hasabo; Mohamed Ibrahim Abdelraoof; Mohamed Alshandidy; Muhammad Eid; Esraa Menshawy; Oumaima Outani; Ahmed Menshawy
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

5.  Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis.

Authors:  Lina S Silva-Bermudez; Freddy J K Toloza; Maria C Perez-Matos; Russell J de Souza; Laura Banfield; Andrea Vargas-Villanueva; Carlos O Mendivil
Journal:  Endocr Connect       Date:  2020-10       Impact factor: 3.335

Review 6.  Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome.

Authors:  Young-Mo Yang; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2015-09-01       Impact factor: 2.423

Review 7.  Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.

Authors:  Sebastião Freitas de Medeiros
Journal:  Reprod Biol Endocrinol       Date:  2017-12-08       Impact factor: 5.211
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.